Sandbox:Mitra3: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 19: | Line 19: | ||
|C05=• '''In patients with refractory hypotension:'''<br> | |C05=• '''In patients with refractory hypotension:'''<br> | ||
|C06= May be needed in patients with cardiogenic shock secondary to RVMI}} | |C06= May be needed in patients with cardiogenic shock secondary to RVMI}} | ||
{{familytree/end}} | {{familytree/end}} | ||
Revision as of 17:58, 3 August 2020
| Therapuetic Considerations in RVMI | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Reperfusion | Maintenance of RV preload | Decreased RV afterload | Restoring Rate/Rhythm and AV synchrony | Inotropic support | Mechanical Circulatory Support | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
•Thrmobolytics •Percutaneous coronary intervention (PCI) | • Avoidance of preload reducing agents, such as:
| • Systemic or pulmonary vasodilators: | • In patients with bradyarrhthmias: | • In patients with refractory hypotension: | May be needed in patients with cardiogenic shock secondary to RVMI | {{{ }}} | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||